1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
RaySearch Laboratories AB (publ)

RaySearch Laboratories AB (publ)

RSLBF
RaySearch Laboratories AB (publ)US flagOther OTC
24.00
USD
- -
- -
822.79MMarket Cap
RaySearch Laboratories AB (publ)
RSLBF
(Other OTC)

Recent

price

24.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.43
3.68
5.36
6.01
8.32
11.6
15.5
17.07
18.3
21.63
19.01
18.72
24.61
29.82
34.77
39.21
38.03
Revenue per Share
0.84
0.5
0.58
-0.61
1.75
2.05
4.42
3.43
2.29
1.47
-0.26
-1.38
0.69
2.38
5.94
6.64
6.54
Basic EPS, GAAP
1.76
-0.85
0.98
-0.74
-0.22
0.22
0.41
-0.04
-1.32
3.15
8.8
5.43
8.96
12.59
13.56
10.47
9.38
Free Cash Flow per Basic Share
0.5
0.5
- -
- -
- -
- -
0.25
- -
- -
- -
- -
- -
- -
- -
2
3
3
Dividend per Share
5.68
5.68
6.34
5.72
7.39
9.44
13.61
17.04
19.33
20.74
20.48
18.49
19.18
21.56
25.49
29.14
- -
Book Value per Share
1.83
1.04
1.52
0.88
2.55
3.63
6.33
7.52
8.17
8.08
6.05
3.07
4.04
5.97
9.58
12.44
13.61
Tangible Book Value per Share
34
34
34
34
34
34
34
34
34
34
34
34
34
34
34
34
34
Basic Weighted Avg Shares
118
126
182
204
285
398
531
585
627
742
652
642
844
1,022
1,192
1,344
1,303
Sales/Revenue/Turnover
33.87
21.81
13.65
-12.44
24.32
22.84
35.42
30.09
11.1
6.61
3.94
-9.98
3.59
11.98
21.09
24.52
21.87
Operating Margin (%)
- -
34
45
53
54
57
67
70
114
183
214
250
297
286
299
291
- -
Depreciation Expense
29
17
20
-21
60
70
151
118
79
50
-9
-47
24
82
204
228
224
Net Income, GAAP
27.98
40.75
15.71
- -
23.98
24.9
23.56
24.55
13.49
19.48
- -
- -
26.55
25.9
22.59
20.85
21.28
Effective Tax Rate (%)
24.54
13.49
10.91
-10.19
20.98
17.66
28.49
20.1
12.52
6.8
-1.39
-7.37
2.82
7.98
17.07
16.95
17.21
Profit Margin (%)
98
79
89
83
156
172
311
311
267
224
149
- -
-9
127
281
401
446
Working Capital
- -
1
- -
- -
41
38
62
10
7
86
54
491
474
432
395
317
299
LT Debt
197
197
218
197
252
320
460
580
657
705
694
628
657
735
877
985
1,043
Total Equity
15.05
8.25
9.91
- -
20.99
20.6
32.35
22.14
8.32
4.78
- -
- -
1.91
7.55
14.9
18.87
16.07
Return on Invested Capital (%)
15.3
8.73
9.68
- -
24.68
21.88
34.29
19.94
11.01
6.66
- -
- -
2.67
7.15
16.1
17.08
54.23
Return on Capital (%)
15.3
8.73
9.68
-10.16
26.7
24.33
38.32
22.39
12.6
7.34
-1.29
-7.08
3.68
11.68
25.23
24.32
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
77
78
78
LT Borrowings
- -
- -
- -
LT Finance Leases
334
317
299
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
34
Market Capitalization
8,931
7,535
6,822

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
911
971
1,009
Cash, Cash Equivalents & STI
323
407
439
Accounts Receivable, Net
209
-9
196
Inventories
26
22
49
Total Current Liabilities
573
570
563
Payables & Accruals
- -
- -
- -
ST Debt
77
78
78
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.77%
7.72%
12.39%
Free Cash Flow
312.61%
10.42%
-22.8%
Net Income, GAAP
58.16%
135.06%
11.94%
Sales/Revenue/Turnover
13.76%
16.1%
12.78%
Total Cash Common Dividend
- -
- -
49.85%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
257
319
293
322
1,192
2025
332
305
332
375
1,344
2026
290
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.07
1.79
1.32
1.75
5.94
2025
1.66
0.9
2.09
2
6.64
2026
1.55
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
2
- -
- -
2
2025
- -
3.01
- -
- -
3
2026
- -
- -
- -
- -
- -
Similar Companies
Oakridge International Limited (OAK.AX)
nDatalyze Corp. (NDATF)
Imaging Biometrics Ltd. (IQAIF)
MultiPlan Corporation (MPLN)
MSP Recovery, Inc. (LIFW)
Signify Health, Inc. (SGFY)
Business
RaySearch Laboratories AB (publ) RaySearch Laboratories AB is a Sweden-based medical technology company that develops advanced software solutions for radiation therapy and oncology, supporting thousands of clinics worldwide in cancer treatment. Founded in 2000 as a spin-off from Karolinska Institutet and headquartered at Eugeniavägen 18 in Stockholm, the company offers core products including RayStation, a flexible treatment planning system with adaptive therapy, multi-criteria optimization, and support for external beam therapy using photons, electrons, protons, helium, and carbon ions as well as HDR brachytherapy; RayPlan, a cost-effective planning system for essential radiation therapy techniques; RayCare, an oncology information system; and DrugLog, a chemotherapy quality assurance solution acquired from Pharmacolog AB. RaySearch operates globally through subsidiaries in the United States, Singapore, Belgium, France, Germany, and the United Kingdom, serving leading cancer centers with professional services in radiation oncology, project management, medical dosimetry, and medical physics. In July 2025, RaySearch entered a strategic partnership with Radiology Oncology Systems to integrate refurbished linear accelerators with its software, enhancing access to advanced cancer care and sustainability in radiation therapy practices while anticipating increased adoption of RayStation and RayCare.

Company News

APIChat

  • seekingalpha.com

    RaySearch Laboratories AB (publ) (RSLBF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    RaySearch Laboratories AB (publ) (RSLBF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    RaySearch Laboratories AB (publ) (RSLBF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    RaySearch Laboratories: Interim report April - June 2025

  • prnewswire.com

    Interim report January 1 - March 31, 2025: RaySearch Laboratories

  • prnewswire.com

    RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO

  • prnewswire.com

    Completed placing of shares in RaySearch Laboratories AB (publ)

  • prnewswire.com

    Contemplated placement of existing shares in RaySearch Laboratories AB

  • prnewswire.com

    RaySearch Laboratories: Year-end report 2024

  • prnewswire.com

    RaySearch Laboratories to present ongoing development in liver ablation therapy* at RSNA 2024

  • prnewswire.com

    RaySearch Laboratories: Interim report July - September 2024

  • prnewswire.com

    RaySearch Laboratories: Interim report April - June 2024

  • prnewswire.com

    RaySearch Laboratories: Interim report January 1 - March 31, 2024

  • prnewswire.com

    RaySearch Laboratories: Year-end report 2023

  • prnewswire.com

    RaySearch Laboratories: Interim report January 1 - September 30, 2023

  • prnewswire.com

    Invitation to presentation of RaySearch's interim report for the third quarter of 2023

  • prnewswire.com

    RaySearch Laboratories : Interim report January 1 - June 30, 2023

  • prnewswire.com

    Invitation to presentation of RaySearch's interim report for the second quarter of 2023

  • prnewswire.com

    UMCG in the Netherlands purchases Micro-RayStation for pre-clinical research, RaySearch Laboratories